STOCK TITAN

Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Ceapro Inc. (OTCQX: CRPOF) announced that its abstract titled "Reprogramming Rogue Macrophages: Yeast Beta-Glucan Microparticles as a Macrophage Modulator for Lung Fibrosis" has been accepted for presentation at the American Thoracic Society International Conference in Washington, DC from May 19-24, 2023. This presentation will showcase findings from a collaboration with McMaster University researchers that investigate the anti-fibrotic properties of Ceapro's yeast beta glucan. The research aims to explore its potential as an inhalable treatment for lung fibrotic diseases.

Positive
  • Acceptance of Ceapro's research abstract for a prestigious conference enhances credibility.
  • Collaboration with McMaster University strengthens research and development efforts.
Negative
  • None.

Oral presentation to highlight unique results from pre-clinical studies demonstrating potential of Ceapro’s yeast beta glucan to reprogram macrophages involved in fibrotic lung diseases

EDMONTON, Alberta, March 23, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the abstract titled, “Reprogramming Rogue Macrophages: Yeast Beta-Glucan Microparticles as a Macrophage Modulator for Lung Fibrosis,” has been accepted for a presentation at the American Thoracic Society (ATS) International Conference to be held at the Walter E. Washington Convention Center in Washington, DC between May 19-24, 2023.

The data to be presented by Mrs. Safaa Naiel, Ph.D. candidate, springs from the expanded research collaboration between Ceapro and McMaster researchers, Dr. Kjetil Ask, Dr. Todd Hoare and Dr. Martin Kolb, which is studying the anti-fibrotic properties of Ceapro’s PGX-Processed yeast beta glucan in experimental models of lung fibrosis and its potential as an inhalable immuno-therapeutic/-prophylactic in lung fibrotic diseases.

For more information about the conference, please visit the event website here.

About McMaster University

McMaster University, one of four Canadian universities listed among the Top 100 universities in the world, is renowned for its innovation in both learning and discovery. It has a student population of 23,000 and more than 175,000 alumni in 140 countries.

McMaster University is a globally renowned institution of higher learning and an innovative research community committed to advancing human and societal health and well-being. Our focus on collaboratively exchanging ideas and approaches makes us uniquely positioned to pioneer ground-breaking solutions to real-world problems leading to a Brighter World. 

About the American Thoracic Society

Founded in 1905, the American Thoracic Society is the world's leading medical society dedicated to accelerating the advancement of global respiratory health through multidisciplinary collaboration, education, and advocacy. The Society’s involves more than 16,000 members focused on leading scientific discoveries, advancing professional development, impacting global health, and transforming patient care. 

About Ceapro Inc. 

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com

For more information contact: 
Jenene Thomas 
JTC Team, LLC 
Investor Relations and Corporate Communications Advisor 
T (US): +1 (833) 475-8247 
E: czo@jtcir.com 

Issuer:
Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release


FAQ

What is the significance of Ceapro's research presented at the ATS International Conference?

Ceapro's research highlights the potential of yeast beta glucan in treating lung fibrosis, which could attract attention and funding.

When and where will Ceapro present its research on yeast beta glucan?

Ceapro will present its research at the American Thoracic Society International Conference in Washington, DC, from May 19-24, 2023.

What research collaboration is highlighted in Ceapro's recent press release?

The press release emphasizes a collaboration with McMaster University focusing on the anti-fibrotic properties of Ceapro's yeast beta glucan.

What is the focus of Ceapro's abstract accepted for the ATS Conference?

The focus is on reprogramming macrophages using yeast beta glucan to combat fibrotic lung diseases.

CEAPRO INC

OTC:CRPOF

CRPOF Rankings

CRPOF Latest News

CRPOF Stock Data

13.31M
76.19M
4.01%
Biotechnology
Healthcare
Link
United States of America
Edmonton